Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Liposomes Expand Cancer Drug's Bioavailability and Potency in Mouse Model

By BiotechDaily International staff writers
Posted on 16 May 2013
Image: First author Dr. Carey Anders (Photo courtesy of the University of North Carolina, Lineberger Comprehensive Cancer Center).
Image: First author Dr. Carey Anders (Photo courtesy of the University of North Carolina, Lineberger Comprehensive Cancer Center).
Encapsulation of the anticancer drug doxorubicin (doxo) within PEGylated liposomes increased the compound's intracranial tumor bioavailability, extended its lifetime in circulation, and improved the survival rate of mice bearing intercranial triple negative breast tumors.

Investigators at the University of North Carolina (Chapel Hill, USA) sought to decrease the toxicity of doxo and increase the length of time it could circulate in the blood by enclosing the drug within PEGylated liposomes.

The investigators inoculated athymic mice intracerebrally with triple negative breast cancer cells that expressed the enzyme luciferase. They then treated some of the animals with doxo ecapslulated in PEGylated liposomes (PLD) or with free doxo (NonL-doxo). Efficacy of the treatment was assessed by survival of the animals and detection of bioluminescence.

Results published in the May 1, 2013, issue of the journal PLOS ONE revealed that treatment with PLD resulted in a 1,500-fold higher plasma and 20-fold higher intracranial tumor bioavailability compared with NonL-doxo. In addition, PLD was detected in plasma and intracranial tumors 96 hours following treatment compared to the drug being undetectable in plasma and tumors after 24 hours in the NonL-doxo animals. Survival rates for the PLD treated mice were significantly prolonged as compared NonL-doxo.

Related Links:

University of North Carolina


Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.